|
|
Neurology July 2009
Volume 73
Issue 2
| This Week in Neurology(R) |
this week in neurology(r): highlights of the july 14 issue.
Pages: 83
|
| Editorials |
patent foramen ovale and ischemic stroke recurrence: the end of a never-ending story?.
- Tamayo, Arturo, Harrer, Judith. Pages: 84-85
|
familial neurodegeneration in progressive supranuclear palsy: more frequent than expected?.
- Pastor, Pau, MD, PhD. Pages: 86-87
|
| In Memoriam |
george karpati, md, faan (1934-2009).
- Griggs, Robert, MD, FAAN, Engel, Andrew, MD, FAAN. Pages: 88
|
| Articles |
recurrent cerebral ischemia in medically treated patent foramen ovale: a meta-analysis .
- Almekhlafi, M, Wilton, S, MD, FRCPC, Rabi, D, MD, MSc, Ghali, W, MD, MPH, Lorenzetti, D, Hill, M, MD, MSc. Pages: 89-97
>
Show/Hide Abstract
Background: Among patients with a patent foramen ovale (PFO) and a prior cryptogenic ischemic stroke or TIA, the absolute and relative risk of recurrent events is unclear.Methods: We conducted a systematic review and meta-analysis of clinical studies in any language published up to February 2008. We included studies reporting original data on recurrent cerebrovascular events in patients with prior cryptogenic stroke or TIA and PFO. Two authors independently extracted data and evaluated study quality.Results: We identified 15 eligible studies, four with a non-PFO comparison group. In these four studies, the pooled relative risk (RR) for recurrent ischemic stroke or TIA in patients with vs without a PFO was 1.1 (95% confidence interval [CI] 0.8 to 1.5). For ischemic stroke, the pooled RR was 0.8 (95% CI 0.5 to 1.3). We tabulated the absolute rate of recurrent events in all 15 studies. The pooled absolute rate of recurrent ischemic stroke or TIA in patients with PFO was 4.0 events per 100 person-years (95% CI 3.0 to 5.1) while the rate of recurrent ischemic stroke was 1.6 events per 100 person-years (95% CI 1.1 to 2.1).Conclusions: In medically treated patients with prior cryptogenic stroke, while the absolute rate of recurrent events is variable, available evidence does not support an increased relative risk of recurrent ischemic events in those with vs without a patent foramen ovale. Patent foramen ovale closure in these patients cannot be recommended until the results of ongoing clinical trials are reported.(C)2009AAN Enterprises, Inc.
|
familial aggregation of parkinsonism in progressive supranuclear palsy.
- Kaat, L, Boon, A, MD, PhD, Azmani, A, Kamphorst, W, Breteler, M, MD, PhD, Anar, B, Heutink, P, van Swieten, J, MD, PhD. Pages: 98-105
>
Show/Hide Abstract
Background: Progressive supranuclear palsy (PSP) is a progressive neurodegenerative disorder characterized by aggregates of the microtubule-associated protein tau (MAPT). A nonsignificant trend for positive family history has been observed in two case-control studies and several pedigrees with familial clustering of parkinsonism have been described. Occasionally, mutations in MAPT are found in patients with a clinical phenotype similar to PSP. In this case-control study, we compared the occurrence of dementia and parkinsonism among first-degree relatives of patients with PSP with an age- and sex-matched control group.Methods: Family history of dementia and parkinsonism was collected from all first-degree relatives of patients with PSP who fulfilled the international National Institute of Neurological Disorders and Stroke criteria for PSP. Age- and sex-matched controls were selected from the Rotterdam Study. Genetic testing and pathologic examination was performed in a subset of familial PSP cases.Results: Fifty-seven (33%) of the 172 patients with PSP had at least one first-degree relative who had dementia or parkinsonism compared to 131 (25%) of the control subjects (odds ratio [OR] 1.5, 95% confidence interval [CI] 1.01-2.13). In patients with PSP, more first-degree relatives with parkinsonism were observed compared to controls, with an OR 3.9 (95% CI 1.99-7.61). Twelve patients with PSP (7%) fulfilled the criteria for an autosomal dominant mode of transmission. The intrafamilial phenotype within these pedigrees varied among PSP, dementia, tremor, and parkinsonism. Genetic studies revealed one patient with a P301L mutation in MAPT. Pathologic examination of five familial cases confirmed the clinical diagnosis of PSP, with predominant four repeat tau pathology in affected brain areas.Conclusion: This study demonstrates familial aggregation of parkinsonism in progressive supranuclear palsy.(C)2009AAN Enterprises, Inc.
|
dopamine cell loss in the periaqueductal gray in multiple system atrophy and lewy body dementia.
- Benarroch, E, MD, DSci, Schmeichel, A, Dugger, B, Sandroni, P, MD, PhD, Parisi, J, Low, P. Pages: 106-112
>
Show/Hide Abstract
Background: Experimental studies indicate that dopaminergic neurons in the ventral periaqueductal gray matter (PAG) are involved in maintenance of wakefulness. Excessive daytime sleepiness (EDS) is a common manifestation of multiple system atrophy (MSA) and dementia with Lewy bodies (DLB) but involvement of these neurons has not yet been explored.Methods: We sought to determine whether there is loss of dopaminergic neurons in the ventral PAG in MSA and DLB. We studied the midbrain obtained at autopsy from 12 patients (9 male, 3 female, age 61 +/- 3) with neuropathologically confirmed MSA, 12 patients (11 male, 1 female, age 79 +/- 4) with diagnosis of DLB and limbic or neocortical Lewy body disease, and 12 controls (7 male, 5 female, ages 67 +/- 4). Fifty-micron sections were immunostained for tyrosine hydroxylase (TH) or [alpha]-synuclein and costained with thionin. Cell counts were performed every 400 [mu]m throughout the ventral PAG using stereologic techniques.Results: Compared to the total estimated cell numbers in controls (21,488 +/- 8,324 cells), there was marked loss of TH neurons in the ventral PAG in both MSA (11,727 +/- 5,984; p < 0.01) and DLB (5,163 +/- 1,926; p < 0.001) cases. Cell loss was more marked in DLB than in MSA. There were characteristic [alpha]-synuclein inclusions in the ventral PAG in both MSA and DLB.Conclusions: There is loss of putative wake-active ventral periaqueductal gray matter dopaminergic neurons in both multiple system atrophy and dementia with Lewy bodies, which may contribute to excessive daytime sleepiness in these conditions.(C)2009AAN Enterprises, Inc.
|
cerebellar magnetic stimulation decreases levodopa-induced dyskinesias in parkinson disease.
- Koch, G, MD, PhD, Brusa, L, MD, PhD, Carrillo, F, Lo Gerfo, E, Torriero, S, Oliveri, M, MD, PhD, Mir, P, MD, PhD, Caltagirone, C, Stanzione, P. Pages: 113-119
>
Show/Hide Abstract
Background: The neural mechanisms and the circuitry involved in levodopa-induced dyskinesia (LID) are still partially obscure. LID can be considered the consequence of an abnormal pattern or code of activity that originates and is conveyed from the basal ganglia to the thalamus and the cortical motor areas. However, not only striatothalamocortical motor circuits but also other interconnected pathways could be implicated in its pathogenesis.Methods: In a series of experiments, we applied repetitive transcranial magnetic stimulation (rTMS) over the lateral cerebellum in a group of patients with advanced Parkinson disease, to investigate whether modulation of cerebellothalamocortical circuits by means of rTMS may result in a modification of a dyskinetic state induced by levodopa ingestion.Results: We found that a single session of cerebellar continuous theta burst stimulation (cTBS) was capable of transiently reducing LID. In the same patients, we observed that cerebellar cTBS changed the profile of activation of intracortical circuits in the contralateral primary motor cortex. Cerebellar cTBS reduced short intracortical inhibition and increased long intracortical inhibition, inducing a cortical reorganization that is associated with a reduction of LID. Furthermore, in another experiment, we observed that a 2-week course of bilateral cerebellar cTBS induced persistent clinical beneficial effects, reducing peak-dose LID for up to 4 weeks after the end of the daily stimulation period.Conclusions: Our study demonstrates that cerebellar continuous theta burst stimulation has an antidyskinetic effect in Parkinson disease patients with levodopa-induced dyskinesia, possibly due to modulation of cerebellothalamocortical pathways.(C)2009AAN Enterprises, Inc.
|
cognitive impairment risk: white matter hyperintensity progression matters.
- Silbert, Lisa, MD, MCR, Howieson, Diane, Dodge, Hiroko, Kaye, Jeffrey. Pages: 120-125
>
Show/Hide Abstract
Objective: To determine whether white matter hyperintensity (WMH) progression rate is a better predictor of cognitive impairment risk than baseline WMH volume in healthy elderly individuals.Method: Ninety-eight cognitively intact elderly subjects were followed in the Oregon Brain Aging Study. Forty-nine had at least 3 brain MRIs and annual cognitive and neurologic assessments until diagnosed with persistent cognitive impairment (PCI). Brain, ventricular CSF (vCSF), intracranial volume (ICV), hippocampus, total WMH, periventricular (PV) WMH, and subcortical WMH volumes were measured. Cox proportional hazards survival analyses were used to assess cognitive impairment risk.Results: After adjusting for age, apolipoprotein E4 status, incident hypertension, ICV, entry Mini-Mental State Examination, baseline hippocampus, and both baseline vCSF volume and rate of vCSF volume change, increased progression of total WMH volume (hazard ratio [HR] 1.84, 95% confidence interval [CI] 1.3-2.7, p = 0.0007) and PV WMH volume (HR 1.94, 95% CI 1.3-3.1, p = 0.001) conferred higher risk of PCI, whereas baseline WMH volumes did not. Every 1 mL/y increase in PV WMH volume was associated with a 94% increased risk of PCI.Conclusion: Progression of total and periventricular (PV) white matter hyperintensity (WMH) volumes are better predictors of persistent cognitive impairment (PCI) than baseline WMH burden. Greater PV WMH burden progression is associated with the development of PCI, a potential precursor to Alzheimer or vascular dementia. Identification of factors that decrease WMH accumulation over time is needed to maintain cognitive health in our growing elderly population.(C)2009AAN Enterprises, Inc.
|
| Special Article |
practice parameter update: management issues for women with epilepsy-focus on pregnancy (an evidence-based review): obstetrical complications and change in seizure frequency: report of the quality standards subcommittee and therapeutics and technology assessment subcommittee of the american academy of neurology and american epilepsy society .
- Harden, C, Hopp, J, Ting, T, Pennell, P, French, J, Hauser, W, Wiebe, S, Gronseth, G, Thurman, D, MD, MPH, Meador, K, Koppel, B, Kaplan, P, MB, FRCP, Robinson, J, Gidal, B, Hovinga, C, Wilner, A, Vazquez, B, Holmes, L, Krumholz, A, Finnell, R, Le Guen, C. Pages: 126-132
>
Show/Hide Abstract
Objective: To reassess the evidence for management issues related to the care of women with epilepsy (WWE) during pregnancy, including the risk of pregnancy complications or other medical problems during pregnancy in WWE compared to other women, change in seizure frequency, the risk of status epilepticus, and the rate of remaining seizure-free during pregnancy.Methods: A 20-member committee including general neurologists, epileptologists, and doctors in pharmacy evaluated the available evidence based on a structured literature review and classification of relevant articles published between 1985 and February 2008.Results: For WWE taking antiepileptic drugs, there is probably no substantially increased risk (greater than two times expected) of cesarean delivery or late pregnancy bleeding, and probably no moderately increased risk (greater than 1.5 times expected) of premature contractions or premature labor and delivery. There is possibly a substantially increased risk of premature contractions and premature labor and delivery during pregnancy for WWE who smoke. Seizure freedom for at least 9 months prior to pregnancy is probably associated with a high likelihood (84%-92%) of remaining seizure-free during pregnancy.Recommendations: Women with epilepsy (WWE) should be counseled that seizure freedom for at least 9 months prior to pregnancy is probably associated with a high rate (84%-92%) of remaining seizure-free during pregnancy (Level B). However, WWE who smoke should be counseled that they possibly have a substantially increased risk of premature contractions and premature labor and delivery during pregnancy (Level C).(C)2009AAN Enterprises, Inc.
|
practice parameter update: management issues for women with epilepsy-focus on pregnancy (an evidence-based review): teratogenesis and perinatal outcomes: report of the quality standards subcommittee and therapeutics and technology assessment subcommittee of the american academy of neurology and american epilepsy society symbol .
- Harden, C, Meador, K, Pennell, P, Hauser, W, Gronseth, G, French, J, Wiebe, S, Thurman, D, MD, MPH, Koppel, B, Kaplan, P, MB, FRCP, Robinson, J, Hopp, J, Ting, T, Gidal, B, Hovinga, C, Wilner, A, Vazquez, B, Holmes, L, Krumholz, A, Finnell, R, Hirtz, D, Le Guen, C. Pages: 133-141
>
Show/Hide Abstract
Objective: To reassess the evidence for management issues related to the care of women with epilepsy (WWE) during pregnancy.Methods: Systematic review of relevant articles published between January 1985 and June 2007.Results: It is highly probable that intrauterine first-trimester valproate (VPA) exposure has higher risk of major congenital malformations (MCMs) compared to carbamazepine and possible compared to phenytoin or lamotrigine. Compared to untreated WWE, it is probable that VPA as part of polytherapy and possible that VPA as monotherapy contribute to the development of MCMs. It is probable that antiepileptic drug (AED) polytherapy as compared to monotherapy regimens contributes to the development of MCMs and to reduced cognitive outcomes. For monotherapy, intrauterine exposure to VPA probably reduces cognitive outcomes. Further, monotherapy exposure to phenytoin or phenobarbital possibly reduces cognitive outcomes. Neonates of WWE taking AEDs probably have an increased risk of being small for gestational age and possibly have an increased risk of a 1-minute Apgar score of <7.Recommendations: If possible, avoidance of valproate (VPA) and antiepileptic drug (AED) polytherapy during the first trimester of pregnancy should be considered to decrease the risk of major congenital malformations (Level B). If possible, avoidance of VPA and AED polytherapy throughout pregnancy should be considered to prevent reduced cognitive outcomes (Level B). If possible, avoidance of phenytoin and phenobarbital during pregnancy may be considered to prevent reduced cognitive outcomes (Level C). Pregnancy risk stratification should reflect that the offspring of women with epilepsy taking AEDs are probably at increased risk for being small for gestational age (Level B) and possibly at increased risk of 1-minute Apgar scores of <7 (Level C).(C)2009AAN Enterprises, Inc.
|
practice parameter update: management issues for women with epilepsy-focus on pregnancy (an evidence-based review): vitamin k, folic acid, blood levels, and breastfeeding: report of the quality standards subcommittee and therapeutics and technology assessment subcommittee of the american academy of neurology and american epilepsy society .
- Harden, C, Pennell, P, Koppel, B, Hovinga, C, Gidal, B, Meador, K, Hopp, J, Ting, T, Hauser, W, Thurman, D, MD, MPH, Kaplan, P, MB, FRCP, Robinson, J, French, J, Wiebe, S, Wilner, A, Vazquez, B, Holmes, L, Krumholz, A, Finnell, R, Shafer, P, RN, MN, Le Guen, C. Pages: 142-149
>
Show/Hide Abstract
Objective: To reassess the evidence for management issues related to the care of women with epilepsy (WWE) during pregnancy, including preconceptional folic acid use, prenatal vitamin K use, risk of hemorrhagic disease of the newborn, clinical implications of placental and breast milk transfer of antiepileptic drugs (AEDs), risks of breastfeeding, and change in AED levels during pregnancy.Methods: A 20-member committee evaluated the available evidence based on a structured literature review and classification of relevant articles published between 1985 and October 2007.Results: Preconceptional folic acid supplementation is possibly effective in preventing major congenital malformations in the newborns of WWE taking AEDs. There is inadequate evidence to determine if the newborns of WWE taking AEDs have a substantially increased risk of hemorrhagic complications. Primidone and levetiracetam probably transfer into breast milk in amounts that may be clinically important. Valproate, phenobarbital, phenytoin, and carbamazepine probably are not transferred into breast milk in clinically important amounts. Pregnancy probably causes an increase in the clearance and a decrease in the concentration of lamotrigine, phenytoin, and to a lesser extent carbamazepine, and possibly decreases the level of levetiracetam and the active oxcarbazepine metabolite, the monohydroxy derivative.Recommendations: Supplementing women with epilepsy with at least 0.4 mg of folic acid before they become pregnant may be considered (Level C). Monitoring of lamotrigine, carbamazepine, and phenytoin levels during pregnancy should be considered (Level B) and monitoring of levetiracetam and oxcarbazepine (as monohydroxy derivative) levels may be considered (Level C). A paucity of evidence limited the strength of many recommendations.(C)2009AAN Enterprises, Inc.
|
| Clinical/Scientific Notes |
seropositive myasthenia gravis: a nationwide epidemiologic study.
- Heldal, Anne, Owe, Jone, Gilhus, Nils, Erik MD, PhD, Romi, Fredrik, MD, PhD. Pages: 150-151
|
long-term superiority of subthalamic nucleus stimulation over pallidotomy in parkinson disease.
- Esselink, R, MD, PhD, de Bie, R, MD, PhD, de Haan, R, Lenders, M, Nijssen, P, van Laar, T, MD, PhD, Schuurman, P, MD, PhD, Bosch, D, MD, PhD, Speelman, J, MD, PhD. Pages: 151-153
|
| Reflections: Neurology and the Humanities |
the case of the misguided squire.
- Joynt, Robert, MD, PhD. Pages: 154-156
|
| NeuroImages |
idiopathic sphenoidal defects detected by 3d computed tomography.
- Hamaguchi, Ayumi, Takahashi, Ryoichi, Iwasa, Kazuo, MD, PhD, Yamada, Masahito, MD, PhD. Pages: 157-158
|
| Resident & Fellow Section |
right brain: my first tpa.
- Robbins, Matthew. Pages: e9-e10
|
pearls & oy-sters: distal subclavian artery: a source of cerebral embolism.
- Gooneratne, Inuka, Gamage, Ranjanie, Gunarathne, Kamal. Pages: e11-e12
|
| Correspondence |
efficacy and tolerability of levetiracetam versus phenytoin after supratentorial neurosurgery.
- Sethi, Nitin. Pages: 159
|
pronouncing brain death: contemporary practice and safety of the apnea test.
- Jeret, Joseph. Pages: 159-160
|
gastrointestinal bleeding after acute ischemic stroke.
- Misra, Usha, Kalita, Jayantee. Pages: 160-161
|
| Correction |
the common bdnf polymorphism may be a modifier of disease severity in rett syndrome.
Pages: 161
|
| Departments: Book Review |
the pseudotumor cerebri syndrome: pseudotumor cerebri, idiopathic intracranial hypertension, benign intracranial hypertension, and related conditions.
- Friedman, Deborah. Pages: 162-163
|
| Departments: Calendar |
calendar.
Pages: 164
|
| Departments: Changes |
changes.
Pages: 166
|
| Future Issues |
in the next issue of neurology(r): volume 73, number 3, july 21, 2009.
Pages: A42
|
|
|